Alphamab Oncology Ordinary Shares 09966
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HK$2.82
- Day Range
- HK$2.85–3.09
- 52-Week Range
- HK$2.00–13.46
- Bid/Ask
- HK$3.05 / HK$3.06
- Market Cap
- HK$2.95 Bil
- Volume/Avg
- 7.6 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.60
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 429
- Website
- https://www.alphamabonc.com
Comparables
Valuation
|
Metric
|
09966
|
6976
|
06978
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.78 | 2.05 | — |
Price/Sales | 10.60 | 1,185.36 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
09966
6976
06978
Financial Strength
|
Metric
|
09966
|
6976
|
06978
|
|---|---|---|---|
Quick Ratio | 4.42 | 59.63 | 0.36 |
Current Ratio | 4.61 | 60.01 | 0.38 |
Interest Coverage | −25.20 | −94.19 | −37.83 |
Quick Ratio
09966
6976
06978
Profitability
|
Metric
|
09966
|
6976
|
06978
|
|---|---|---|---|
Return on Assets (Normalized) | −8.50% | −5.20% | −24.06% |
Return on Equity (Normalized) | −11.48% | −5.51% | −267.27% |
Return on Invested Capital (Normalized) | −12.12% | −8.30% | −30.83% |
Return on Assets
09966
6976
06978
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Sddgkmlht | Kmp | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Qcygmvbd | Jmmpyd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mlgdwfhby | Ygwdjyc | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jcgcjhd | Mrmrst | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Bqfpqwmss | Zbj | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Zslckjrc | Bywmd | $28.1 Bil | |||
| Moderna Inc
MRNA
| Ghnnlcpvx | Dvgml | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qfddrxjr | Tzdly | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qvflycrmq | Xrqgxk | $13.4 Bil | |||
| Incyte Corp
INCY
| Frpsjnkwh | Mhkdmsy | $12.7 Bil |
United States